OSI's financial assets, which include significant DPIV
patent royalties, substantial cash, investments and marketable securities, and net operating loss carryforwards of over $700 million as of December 31, 2009, are estimated to be worth approximately $1.
These more recent studies, however, do not provide the full-field velocity data of polymer melts that is possible with DPIV
We are pleased to see the expanded use of this patent estate as new products in the significant emerging market for DPIV
inhibitors are being brought forward," stated Anker Lundemose, M.
Glucose lowering effects and pharmacokinetics of 14-day treatment with the prandial DPIV
inhibitor, PSN9301, in patients with type 2 diabetes - Rachman, Jonathan et al (Abstract # 546-P)
We believe that this license further validates the strength of our DPIV
related patent estate and the importance of this target to the development of innovative new medicines for the treatment of diabetes," stated Anker Lundemose, M.
The development of inhibitors of DPIV
(an enzyme catalyzing the breakdown of the natural hormone glucagon-like peptide-1 (GLP-1)) has become a very competitive area in the type 2 diabetes field.
PSN9301 is a novel oral DPIV
inhibitor currently undergoing Phase II clinical trials where its efficacy and safety are being evaluated in type 2 diabetic patients.
The Company secured two additional non-exclusive licensees to its DPIV
inhibitor patent estate.
NASDAQ: OSIP) announced today that its diabetes and obesity business unit, (OSI) Prosidion, has granted a worldwide non-exclusive license under its DPIV
patent portfolio to a major Japanese pharmaceutical company.
6,890,898 and foreign equivalents thereof which claim combination therapy comprising administration of a DPIV
inhibitor and another therapeutic agent for the treatment of type 2 diabetes and related indications.
6,890,898 which claims combination therapy for modifying glucose metabolism comprising administration of a DPIV
inhibitor and a further therapeutic agent e.
Since 1998, DPIV
has assisted pharmaceutical companies with every aspect of their post-marketing surveillance and risk-management needs.